IntelGenx Technologies Corp.
IGX
Rang in aandelen
#28120
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise... IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Aandeelprijs
$0.17446996
Laatst gesynchroniseerd: 2024-06-11
Marktkapitalisatie
$26.97M
Verandering (1 dag)
-0.57%
Verandering (1 jaar)
2.63%
Land
CA
Handel IntelGenx Technologies Corp. (IGX)
Categorie
Healthcare
Winst voor IntelGenx Technologies Corp. (IGX)
Winst in Mar 2024 TTM: $-11.03M
Volgens de meest recente financiële verslagen van IntelGenx Technologies Corp. bedraagt de huidige winst van het bedrijf $-11.03M. In 2022 behaalde het bedrijf een winst van $-10.69M, een daling ten opzichte van de winst van 2021, die $-9.32M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van IntelGenx Technologies Corp. van 2003 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-11.03M | 11.11% |
| 2023 | $-9.93M | -7.14% |
| 2022 | $-10.69M | 14.72% |
| 2021 | $-9.32M | 32.28% |
| 2020 | $-7.04M | -33.92% |
| 2019 | $-10.66M | 5.46% |
| 2018 | $-10.11M | 231.30% |
| 2017 | $-3.05M | 158.56% |
| 2016 | $-1.18M | -191.40% |
| 2015 | $1.29M | -173.94% |
| 2014 | $-1.75M | 6.53% |
| 2013 | $-1.64M | -27.16% |
| 2012 | $-2.25M | -8.24% |
| 2011 | $-2.45M | -20.80% |
| 2010 | $-3.10M | 49.51% |
| 2009 | $-2.07M | -30.00% |
| 2008 | $-2.96M | 153.92% |
| 2007 | $-1.16M | 49.13% |
| 2006 | $-781.14K | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -47,923.21% |
US
|
|
| $-3.09B | 27,887.31% |
US
|
|
| $-4.02B | 36,311.57% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -17,784.95% |
NL
|
